Analysts’ Weekly Ratings Updates for Legend Biotech (LEGN)

Several analysts have recently updated their ratings and price targets for Legend Biotech (NASDAQ: LEGN):

• 5/20/2026 – Legend Biotech was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 5/18/2026 – Legend Biotech had its “buy” rating reaffirmed by HC Wainwright. They now have a $50.00 price target on the stock.
• 5/13/2026 – Legend Biotech had its price target raised by Royal Bank Of Canada from $62.00 to $64.00. They now have an “outperform” rating on the stock.
• 5/13/2026 – Legend Biotech had its price target raised by TD Cowen to $29.00. They now have a “hold” rating on the stock.
• 5/13/2026 – Legend Biotech had its price target lowered by Morgan Stanley from $49.00 to $48.00. They now have an “overweight” rating on the stock.
• 5/6/2026 – Legend Biotech was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 4/21/2026 – Legend Biotech had its “buy” rating reaffirmed by HC Wainwright. They now have a $50.00 price target on the stock.
• 4/15/2026 – Legend Biotech had its “buy” rating reaffirmed by HC Wainwright. They now have a $50.00 price target on the stock.

Insiders Place Their Bets

In related news, CEO Ying Huang sold 9,936 shares of the firm’s stock in a transaction on Wednesday, March 25th. The shares were sold at an average price of $8.77, for a total value of $87,138.72. Following the completion of the transaction, the chief executive officer owned 247,438 shares of the company’s stock, valued at approximately $2,170,031.26. This trade represents a 3.86% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.02% of the company’s stock.

Legend Biotech (NASDAQ: LEGN) is a commercial-stage biopharmaceutical company specializing in the development and commercialization of chimeric antigen receptor T-cell (CAR-T) therapies for oncology. Headquartered in Somerset, New Jersey, with research and development operations in Shanghai, the company leverages a global infrastructure to advance innovative cellular therapies. Legend Biotech pursues a strategy of strategic collaboration to extend its reach, most notably through its partnership with Janssen Biotech, a subsidiary of Johnson & Johnson.

The company’s lead asset, ciltacabtagene autoleucel (commercially marketed as Carvykti), is a B-cell maturation antigen (BCMA)–directed CAR-T therapy for the treatment of relapsed or refractory multiple myeloma.